Evaluation of ventricular function in patients treated with mitoxantrone and 4'-epidoxorubicin

Serial assessment of ventricular function by means of radionuclide angiography was performed in previously untreated patients with lymphoproliferative diseases who received either 4'epidoxorubicin or mitoxantrone for longer than 6 months. No changes were observed in left ventricular function in...

Full description

Saved in:
Bibliographic Details
Published inArchivos del Instituto de Cardiologia de Mexico Vol. 59; no. 6; p. 615
Main Authors Avilés, A, Díaz-Maqueo, J C, Arévila-Ceballos, N, García Fernández, R, López-Vancell, D, Torras, V
Format Journal Article
LanguageSpanish
Published Mexico 01.11.1989
Subjects
Cardiomyopathies - chemically induced
Cardiomyopathies - diagnostic imaging
Cardiomyopathies - physiopathology
Epirubicin - adverse effects
Epirubicin - pharmacology
Humans
Lymphoma - drug therapy
Mitoxantrone - adverse effects
Mitoxantrone - pharmacology
Radionuclide Imaging
Stroke Volume - drug effects
Online AccessGet more information

Cover

More Information
Summary:Serial assessment of ventricular function by means of radionuclide angiography was performed in previously untreated patients with lymphoproliferative diseases who received either 4'epidoxorubicin or mitoxantrone for longer than 6 months. No changes were observed in left ventricular function in patients received mitoxantrone at doses ranged 90 to 165 mg (mean 113 mg). Three patients (7%) in 4'epidoxorubicin group showed less than or equal to 10% drop in left ventricular ejection, but without clinical manifestations. The doses in this group were 420 to 810 mg (mean 610 mg). We felt that patients without high-risk factors (radiotherapy to mediastinum or previously anthracycline therapy) could be treated with high doses of both drugs and that radionuclide angiography is a useful method for monitoring cardiotoxicity of antineoplastic drugs.
ISSN:0020-3785